Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in support of Project Twenty21, Europe’s first and largest national medical cannabis registry.
By the end of 2021, Project Twenty21 aims to recruit up to 20,000 patients suffering from conditions including anxiety, chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, substance use disorder and Tourette’s Syndrome. It will help them access subsidized medical cannabis while simultaneously gathering evidence of efficacy.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
